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Abstract
Background Hepatotoxicity may be a concern when prescribing antidepressants. Nevertheless, this risk remains poorly 
understood for serotonin and noradrenaline reuptake inhibitors (SNRIs: venlafaxine, milnacipran, duloxetine) and ‘other 
antidepressants’ (mianserin, mirtazapine, tianeptine and agomelatine), particularly in comparison with selective serotonin 
reuptake inhibitors (SSRIs: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram), which are by far the 
most commonly prescribed antidepressants.
Objective We quantified the risk of serious liver injury associated with new use of SNRIs and ‘other antidepressants’ com-
pared with SSRIs in real-life practice.
Methods Based on the French national health insurance database, this cohort study included 4,966,825 individuals aged 
25 years and older with a first reimbursement of SSRIs, SNRIs or ‘other antidepressants’ between January 2010 and June 
2015. We compared the risk of serious liver injury within the 6 months following antidepressant initiation according to anti-
depressant class, with SSRIs as the reference, using an inverse probability-of-treatment-weighted Cox proportional hazard 
model adjusted for demographic characteristics and risk factors of liver injury.
Results We identified 382 serious liver injuries overall (none for milnacipran initiators). Age and gender standardized 
incidence rates per 100,000 person-years were 19.2 for SSRIs, 22.2 for venlafaxine, 12.6 for duloxetine, 21.5 for mianserin, 
32.8 for mirtazapine, 31.6 for tianeptine and 24.6 for agomelatine initiators. Initiation of antidepressants of interest versus 
SSRIs was not associated with an increased risk of serious liver injury [adjusted hazard ratios (95% confidence interval): 
venlafaxine 1.17 (0.83–1.64), duloxetine 0.54 (0.28–1.02), mianserin 0.90 (0.58–1.41), mirtazapine 1.17 (0.67–2.02), tian-
eptine 1.35 (0.82–2.23) and agomelatine 1.07 (0.51–2.23)]. This finding was confirmed by the results of an additional study 
using a case-time-control design.
Conclusion These results do not provide evidence of an increased risk of serious liver injury following initiation of SNRIs 
or ‘other antidepressants’ compared with SSRIs in real-life practice. This could reflect an inherent lack of difference in risk 
between the drug classes, or the fact that individuals with higher susceptibility to drug-induced liver injury are not prescribed 
drugs considered to be more hepatotoxic.
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article (https ://doi.org/10.1007/s4026 3-018-0537-1) contains 
supplementary material, which is available to authorized users.
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Key Points 
This cohort study, which included 4,966,825 antidepres-
sant initiators identified in the French national health 
insurance database, did not identify any significant 
increased risk of serious liver injury associated with 
serotonin and noradrenaline reuptake inhibitors and 
‘other antidepressants’ compared with selective seroto-
nin reuptake inhibitors.
In real-life practice, the risk of serious liver injury does 
not seem to differ markedly across antidepressants 
proposed as first line. This could reflect an inherent lack 
of difference in risk between the drug classes, or the 
fact that individuals with higher susceptibility to drug-
induced liver injury are not prescribed drugs considered 
to be more hepatotoxic.
1  Background
Drug-induced liver injuries (DILIs) are a leading cause of 
acute liver failure [1], post-marketing warnings and with-
drawal of drugs from the market [2]. DILIs have a reported 
incidence between 1 and 19 per 100,000 patient years, which 
is likely to be underestimated [3, 4], the risk emerging only 
once a drug is widely prescribed [2].
Almost all antidepressants may induce hepatotoxicity, 
even at therapeutic dose [5]. Injuries can be hepatocellu-
lar, cholestatic or mixed [5]. They are usually idiosyncratic, 
unpredictable, with an apparent lack of relationship to dose 
and generally appear between several days and 6 months 
after drug initiation [5]. Among antidepressants initially 
proposed as first-line therapy for major depressive disorders, 
the highest risk has been suggested for agomelatine (a recent 
and novel molecule acting as a melatonin-receptor agonist 
and a selective serotonin receptor antagonist), duloxetine 
[a serotonin and noradrenalin reuptake inhibitor (SNRI)] 
and tianeptine (chemically affiliated to the tricyclic anti-
depressants, with distinct pharmacological properties) [5]. 
Selective serotonin reuptake inhibitors (SSRIs), the most 
commonly prescribed antidepressants, might globally have 
a better safety profile regarding hepatotoxicity [5, 6].
Risk management plans have been developed for ago-
melatine and duloxetine since their release owing to the 
possibility of rare and severe liver injuries raised by pre-
marketing clinical trials [7, 8]. Notably, these molecules 
are contraindicated in patients with pre-existing liver dis-
ease resulting in hepatic impairment and, to date, ago-
melatine is the only antidepressant requiring liver moni-
toring during treatment. Information about antidepressant 
hepatotoxicity mainly ensues from clinical trials and phar-
macovigilance case reports [5]. Observational studies, tai-
lored to evaluate such a risk in real-life conditions, are 
scarce, have limited sample sizes and mainly focused on 
duloxetine [9, 10].
The objective of the present study was to quantify the risk 
of serious liver injury associated with initiation of SNRIs 
(venlafaxine, milnacipran and duloxetine) and ‘other antide-
pressants’ (mianserin, mirtazapine, tianeptine and agomela-
tine) compared with initiation of SSRIs in real-life practice. 
Tricyclic antidepressants and monoamine oxidase inhibitors 
(MAOIs) were outside the scope of the study because of 
their particular safety profile, justifying their second-line use 
for the treatment of major depressive disorders.
2  Methods
2.1  Data Sources
A cohort study was conducted using the French national 
health insurance database [Système National d’Information 
Inter-Régimes de l’Assurance Maladie (SNIIRAM)]. Indi-
viduals were enrolled from January 1, 2010 to June 30, 2015. 
This health insurance database covers almost the entire 
French population (65.3 million inhabitants) with different 
affiliation schemes based on types of employment. For the 
present study, the data relating to beneficiaries of the main 
scheme (the general scheme covering approximately 77% of 
the French population) were used. The SNIIRAM compre-
hensively records the following with corresponding dates: 
outpatient drugs [Anatomical Therapeutic Classification 
(ATC) codes] and medical devices prescribed, reimbursed 
services and procedures, as well as demographic data such 
as age, sex, area of residence (postcode), complementary 
universal health insurance (free access to healthcare for 
people with an annual income < 50% of the poverty thresh-
old) and date of death. The database does not stipulate the 
medical indication for each reimbursement. However, it 
includes information on severe and costly long-term dis-
ease (LTD) for which health expenses are fully reimbursed; 
these are coded according to the International Statistical 
Classification of Diseases and Related Health Problems, 
10th Revision (ICD-10) and the date of LTD diagnosis is 
recorded. An anonymous unique identifier for each patient 
links SNIIRAM information to the national hospital dis-
charge database [Programme de Médicalisation des Sys-
tèmes d’Information (PMSI)], which covers all hospitals 
and provides reasons for admission (in the format of the 
ICD-10) and surgical procedures. Previous observational 
studies using the SNIIRAM and the PMSI have been pub-
lished elsewhere [11–17].
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2.2  Inclusion and Exclusion Criteria
Individuals aged 25 years and older, affiliated to the general 
insurance scheme without changes in health plan during the 
previous 12 months and with a first reimbursement (i.e., no 
antidepressant reimbursed in the previous 6 months) of anti-
depressant (except tricyclic or MAOIs) between January 1, 
2010 and June 30, 2015 were included in the study. Inclusion 
date corresponded to the first date meeting those conditions. 
In order to minimize the collection of non-drug-induced 
liver injury, individuals with a history of acute or chronic 
liver disease, pancreatitis, cancer, human immunodeficiency 
virus infection (HIV), alcohol use disorders identified based 
upon LTD or hospitalization diagnoses or reimbursements of 
specific drugs [Appendix Table 1, see electronic supplemen-
tary material (ESM)] were excluded due to pre-existing or 
possible liver conditions. Individuals with reimbursements 
for antidepressants of several groups (see exposure defini-
tion) within 15 days of inclusion were also excluded.
2.3  Exposure Definition
Eight groups of antidepressant initiators were identified 
depending on the molecule used at inclusion among those 
marketed in France during the study period: (1) SSRIs 
(ATC code, fluoxetine: N06AB03, citalopram: N06AB04, 
paroxetine: N06AB05, sertraline: N06AB06, fluvoxamine: 
N06AB08 or escitalopram: N06AB10), (2) venlafaxine 
(N06AX16), (3) milnacipran (N06AX17), (4) duloxetine 
(N06AX21), (5) mianserin (N06AX03), (6) mirtazapine 
(N06AX11), (7) tianeptine (N06AX14) and (8) agomela-
tine (N06AX22).
2.4  Outcome Definition
The outcome was defined as the occurrence of a serious liver 
injury possibly related to antidepressant exposure (i.e., acute 
form of serious liver injuries), resulting in hospitalization 
within the 6 months following antidepressant initiation. The 
outcome was identified by using the main or related diagno-
ses of incident hospital stays registered in the PMSI (ICD-10 
codes: K71.0, K71.1, K71.2, K71.6, K71.8, K71.9, K72.0, 
K75.2, K75.9, K76.2, K76.7, Z94.4, Appendix Table 2, see 
ESM). A literature search was undertaken to identify ICD-
10 codes having a priori the best positive predictive value 
[18–21]. These codes were then validated by a senior phar-
macologist (BB).
2.5  Follow‑Up
Individuals were followed up for 6 months after antidepres-
sant initiation or up to the first of the following events: seri-
ous liver injury, antidepressant discontinuation (follow-up 
pursued 3 months after discontinuation), switch to another 
antidepressant, cancer, HIV infection, viral hepatitis, change 
in health plan or death.
2.6  Covariates
The following covariates were identified at inclusion date: 
age categories, sex, quintiles of deprivation index of par-
ticipant’s area of residence (reflecting a major part of spa-
tial socioeconomic heterogeneity) [22], complementary 
universal health insurance, prime-prescriber specialty 
(general practitioner, private practice psychiatrist or hos-
pital practitioner) and inclusion year. Reimbursements for 
drugs potentially associated with hepatotoxicity (at least 
one reimbursement, Appendix Table 3, see ESM) [23, 24], 
and immunosuppressant drugs (at least two reimbursements, 
ATC code L04A) were considered respectively in the 6 and 
12 months preceding inclusion (including the date of anti-
depressant initiation).
The following comorbidities were considered on the basis 
of relevant reimbursed medicines (at least two reimburse-
ments, ATC codes), hospital discharge or LTD reports (ICD-
10 diagnosis codes): psychiatric history (based upon psycho-
tropic drug reimbursement or psychiatric disease diagnosis), 
diabetes mellitus (based upon antidiabetic drug reimburse-
ment or diagnosis related to diabetes and its complications), 
cardiac failure (based upon related diagnosis), chronic renal 
failure (based upon related diagnosis), measurable morbid 
obesity (based upon related diagnosis) in the 12 months pre-
ceding inclusion (including the date of antidepressant initia-
tion), measurable history of substance abuse (based upon 
opiate substitution reimbursement or diagnosis related to 
substance abuse) and smoking habits (based upon nicotine 
replacement therapy reimbursement or diagnosis related to 
tobacco use) in the 36 months preceding inclusion (includ-
ing the date of antidepressant initiation). Detailed ATC and 
ICD-10 codes used to identify comorbidities are provided 
in Appendix Table 4 (see ESM).
Individuals with reimbursement for aminotransferase 
testing in the month preceding or following inclusion were 
identified as well as those with initiation of drugs potentially 
associated with hepatotoxicity, additional antidepressants or 
aminotransferase testing during the follow-up.
2.7  Statistical Analysis
Antidepressant initiators were described according to the 
distribution of covariates previously mentioned. Sex- and 
age-standardized incidences of serious liver injury were 
computed for each group of antidepressant initiators based 
upon sex and age distribution of SSRI initiators. A uni-
variate Cox proportional hazard model with initiation of 
antidepressant as the main explanatory variable was first 
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used to compare the risk of serious liver injury accord-
ing to initiation of venlafaxine, milnacipran, duloxetine, 
mianserin, mirtazapine, tianeptine and agomelatine versus 
SSRIs. To control for confounding, an inverse probability-
of-treatment-weighted Cox proportional hazard model for 
incident liver injuries was then used. Weights were derived 
from the reciprocal of the propensity scores containing the 
following characteristics assessed at inclusion: age catego-
ries, sex, year of inclusion, deprivation quintiles, comple-
mentary universal health insurance, diabetes, heart failure, 
chronic renal failure, reimbursement for drugs potentially 
associated with hepatotoxicity, reimbursement for immuno-
suppressant drugs, measurable history of substance abuse 
or smoking habits, morbid obesity and aminotransferase 
testing. To reduce instability induced by large weights, the 
stabilized weights were computed and then were truncated 
at the first and 99th percentiles [25]. The standardized dif-
ferences method for assessing balance in observed baseline 
covariates between the SSRIs and each antidepressant of 
interest was applied to compare prevalence of covariates 
in the stabilized weighted sample. Imbalances below 10% 
were considered as negligible [26]. An additional adjust-
ment was made on variables strongly linked with exposure 
(i.e., psychiatric history, prime-prescriber specialty) [27], 
time-varying covariates (i.e., initiation of drugs potentially 
associated with hepatotoxicity or other antidepressants, ami-
notransferase testing during follow-up), and age categories.
2.8  Sensitivity Analysis
In a first sensitivity analysis, the code K72.9 ‘hepatic failure 
unspecified’ was added to the definition of events. Although 
poorly specific, this code was considered to be compatible 
with a potential DILI. In a second sensitivity analysis, the 
follow-up duration was extended to 12 months after antide-
pressant initiation. In a third sensitivity analysis, the sample 
was stratified according to the presence or not of aminotrans-
ferase testing at inclusion to assess the influence of possible 
bias ensuing from differential care related to the forthcoming 
outcome. Finally, a stratification on the number of prescrip-
tions of antidepressant reimbursed during the follow-up (one 
versus more than one, one reimbursement corresponding to 
a maximum 30-day supply) was undertaken to control for 
the bias possibly caused by individuals with a single reim-
bursement, since they were likely to be non-compliant and 
therefore not exposed.
2.9  Secondary Approach: Study Using 
a Case‑Time‑Control Design
A study using a case-time-control design was undertaken 
as a secondary approach to challenge the conclusions of 
the main cohort approach and to better control for residual 
unmeasured confounding; that is, related to variables not 
directly recorded in automated databases and considered as 
unchanged over the study period (e.g., disorders related to 
alcohol abuse, smoking, morbid obesity etc.). One analysis 
was performed for each antidepressant of interest compared 
with SSRIs.
In each analysis, incident cases of serious liver injury 
occurring between September 1, 2011 and June 30, 2015 
were identified using the same criteria as for the main cohort 
approach. Exposure to antidepressants of interest and SSRIs 
was measured both during a ‘risk’ and a ‘reference’ period 
corresponding respectively to the 6 months preceding the 
liver-related event date and to the period from the 9th to 
the 15th month before this date, a 3-month wash-out period 
separating these two time windows.
A conditional logistic regression was used to evaluate 
whether, comparatively to SSRIs, exposure to the antidepres-
sant of interest was more prevalent during the ‘risk’ period 
compared with the ‘reference’ period. Antidepressant users 
considered for analyses were individuals with reimburse-
ments for both (1) SSRIs in the absence of antidepressant of 
interest during one of the two periods and (2) antidepressant 
of interest in the absence of SSRIs during the other period 
(Fig. 1). Odds ratios (ORs), crude and adjusted on covariates 
prone to vary across the periods (i.e., other antidepressants 
and drugs potentially associated with hepatotoxicity), were 
computed.
The particularity of the case-time-control design lies in 
introducing a specific control group to control for temporal 
biases; that is, when the probability of exposure could be 
affected by temporal trends independent of the event of inter-
est (e.g., launch of a new drug, introduction of safety warn-
ings, seasonality, etc.). Therefore, for each case, 20 controls 
of the same sex and age (± 1 year) were randomly sampled 
from the ‘non-case’ population. Exposure was measured 
as for the matched case, and, taking into account exposure 
temporal trends, ORs were derived from the coefficient of 
the interaction between exposure and case or control status 
introduced in the conditional logistic regressions models 
[28].
All statistical tests were two-tailed with an α-risk of 5%. 
Statistical analyses were performed using SAS Enterprise 
Guide software, version 7.1 (SAS Institute Inc.).
3  Results
3.1  Inclusion and Follow‑Up Characteristics 
of Antidepressant Initiators
The study included 4,966,825 antidepressant initiators (Fig. 2). 
Their characteristics at inclusion are described in Table 1. 
Women accounted for 68% of the sample. Mean age was 
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52 years, agomelatine initiators were younger and mianserin, 
mirtazapine and tianeptine initiators were older. Around 8% 
had complementary universal health insurance. Most of the 
time the prime prescriber was a general practitioner. For mil-
nacipran, mirtazapine and agomelatine initiators, the propor-
tion of prescriptions initiated by a private practice psychiatrist 
ranged from 8 to 15% versus < 7% for other groups. Ami-
notransferase testing at inclusion was in place for 35% of ago-
melatine initiators versus around 20% in the other groups. A 
history of psychiatric disorders was more frequently found in 
all groups than among SSRI initiators and was more prevalent 
in the milnacipran, mianserin, mirtazapine and agomelatine 
groups. Diabetes was more frequent in duloxetine, mianserin, 
mirtazapine and tianeptine initiators. Heart failure and chronic 
renal failure were more often found in mianserin, mirtazap-
ine and tianeptine initiators. Mean follow-up was around 
4 months. For 40–50% of initiators, only one reimbursement 
of antidepressant was retrieved during the follow-up (Appen-
dix Table 5, see ESM).
The mean (SD) estimated stabilized weight was 1.00 
(0.31), ranging from 0.35 to 2.18. The standard difference in 
the unweighted model exceeded 10% for 24.9% of the sam-
ple. After weighting by the inverse probability of treatment 
(and stabilization and truncation of the weights), prevalence 
of qualitative categorical variables was similar between each 
antidepressant of interest and SSRIs (Appendix Table 6, see 
ESM).
3.2  Main Approach: Association Between 
Antidepressant of Interest and Serious Liver 
Injury
A total of 382 serious liver injuries were identified (258 
for SSRIs, 36 for venlafaxine, 12 for duloxetine, 29 for 
mianserin, 15 for mirtazapine, 24 for tianeptine, 8 for ago-
melatine, see description in Appendix Table 2, ESM) and 
occurred with a mean delay of 2 months after treatment ini-
tiation. No event was identified for milnacipran. Sex- and 
age-standardized incidence rates per 100,000 person-years 
were 19.2 for SSRIs, 22.2 for venlafaxine, 12.6 for dulox-
etine, 21.5 for mianserin, 32.8 for mirtazapine, 31.6 for tian-
eptine and 24.6 for agomelatine. Initiation of antidepressants 
of interest was not associated with a significant increased 
risk of serious liver injury when compared with SSRIs; 
adjusted hazard ratios (95% CI) 1.17 (0.83–1.64), p = 0.36 
for venlafaxine; 0.54 (0.28–1.02), p = 0.06 for duloxetine; 
0.90 (0.58–1.41), p = 0.64 for mianserin; 1.17 (0.67–2.02), 
p = 0.56 for mirtazapine; 1.35 (0.82–2.23), p = 0.24 for 
tianeptine and 1.07 (0.51–2.23), p = 0.86 for agomelatine. 
Results are summarized in Table 2.
3.3  Sensitivity Analysis
Adding the code K72.9 ‘hepatic failure unspecified’ to the 
main definition of the outcome (37 incident events added) or 
Fig. 1  Exposure to antidepressants of interest and selective serotonin reuptake inhibitors (SSRIs) for cases and controls included in the case-
time-control design according to study period
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extending follow-up from 6 to 12 months (116 events added) 
did not significantly alter the results (Appendix Tables 7 and 
8, see ESM). Conclusions remained unchanged in analyses 
stratified on aminotransferase testing at inclusion and on the 
number of antidepressant prescriptions during the follow-up 
(Appendix Tables 9 and 10, see ESM).
3.4  Secondary Approach: Study Using 
a Case‑Time‑Control Design
In this approach, when comparing exposure during ‘risk’ 
and ‘reference’ periods and using SSRIs as controls, 
the adjusted ORs (95% CI) for antidepressants of inter-
est were 0.94 (0.51–1.72), p = 0.84 for venlafaxine; 0.86 
Fig. 2  Diagram of inclusion. HIV human immunodeficiency virus, SNIIRAM Système National d’Information Inter-Régimes de l’Assurance 
Maladie, SSRIs selective serotonin reuptake inhibitors
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(0.12–5.98), p = 0.88 for milnacipran; 1.15 (0.53–2.53), 
p = 0.72 for duloxetine; 0.91 (0.42–1.97), p = 0.82 for 
mianserin; 1.13 (0.43–3.00), p = 0.80 for mirtazapine; 1.06 
(0.40–2.82), p = 0.91 for tianeptine and 0.87 (0.12–6.34), 
p = 0.89 for agomelatine (Table 3).
4  Discussion
This large prospective observational study conducted in an 
extensive and representative sample of the French popula-
tion did not identify any increased risk of serious liver injury 
associated with the use of SNRIs (venlafaxine, milnacipran 
and duloxetine) or ‘other antidepressants’ (mianserin, mir-
tazapine, tianeptine and agomelatine) when compared with 
SSRIs in real-life practice. This conclusion was supported 
by the results of a case-time-control analysis conducted as 
a secondary approach.
Most of the data concerning antidepressant hepatotoxicity 
ensue from pharmacovigilance and published case reports. 
Some observational studies of limited sample size have pro-
vided information about the hepatotoxicity of duloxetine and 
agomelatine as they were subjected to risk management 
plans. Two observational studies specifically designed to 
evaluate duloxetine hepatotoxicity suggested a higher inci-
dence of liver injuries other than hepatic-related death or 
liver failure with this molecule compared with several other 
antidepressants, but the conclusions were hampered by 
insufficient statistical power [9, 10]. Interestingly, our main 
analysis suggests a trend toward a lower hepatotoxicity of 
duloxetine when compared with SSRIs but this result was 
both non-significant and not confirmed by the secondary 
case-time-control approach. Two observational studies con-
ducted to assess agomelatine safety did not highlight any 
serious case of hepatotoxicity [29, 30], even though they did 
not specifically focus on hepatotoxicity and were not com-
parative. Similarly, our study does not support the existence 
of a higher risk of serious hepatotoxicity for agomelatine ini-
tiators when compared with SSRIs in real conditions of use.
There is clearly a lack of observational studies concern-
ing the potential hepatotoxicity of non-SSRI antidepressants. 
Possible hepatotoxicity of non-SSRI antidepressants was 
deduced from a rise in aminotransferase over the normal 
threshold or rarely by the occurrence of a clinical liver injury 
during pre-marketing clinical trials or post-approval studies 
[6, 31, 32] or in published case reports [33–39].
Several interpretations can be put forward to explain 
the absence of a significant difference in the risk of seri-
ous hepatotoxicity between the antidepressants of interest 
and SSRIs in real-life settings. The first and most obvious 
is that the antidepressants suspected of conveying the high-
est risks of hepatotoxicity are not prescribed to individu-
als believed to present higher susceptibility to DILI (e.g., Ta
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elderly, individuals with diabetes, heart failure, chronic 
renal failure etc.). This is particularly the case for products 
involved in risk management plans such as agomelatine and 
duloxetine, thanks to the information about their hepato-
toxicity provided to prescribers. Second, for particular risk 
situations or if evocative symptoms are identified, it is likely 
that aminotransferases would be monitored and the treatment 
stopped before the occurrence of a serious outcome. How-
ever, this hypothesis is not supported by the fact that strati-
fying on liver monitoring at inclusion did not significantly 
alter the results. Finally, it is worth recalling that this study 
was designed to assess the risk of serious hepatotoxicity, so 
it did not consider infra-clinical or non-serious events, as 
Table 2  Association between initiation of antidepressants of interest versus selective serotonin reuptake inhibitors (SSRIs) and hospitalization 
due to serious liver injury (main definition of event, follow-up 6 months)
CI confidence interval, SSRIs selective serotonin reuptake inhibitors
a Standardized on sex and age categories (< 50 or ≥ 50 years), SSRI initiators served as the reference group
b Inverse probability of treatment weighting considering the following covariates: inclusion year, sex, age, deprivation index and complementary 
universal health insurance at inclusion; diabetes, heart failure, chronic renal failure, measurable history of smoking, morbid obesity and measur-
able history of substance abuse up to 12–36 months before inclusion; reimbursements for drugs potentially associated with hepatotoxicity and 
immunosuppressant drugs up to 6–12 months before inclusion; aminotransferase testing at inclusion ± 1 month
c Additional adjustment on age categories, prescriber specialty at inclusion; psychiatric history in 12 months before inclusion; drugs potentially 
associated with hepatotoxicity, other antidepressants and aminotransferase testing reimbursed during follow-up
Antidepressant Initiators 
(n = 4,966,825)
Events (n = 382) Event incidence (per 100,000 
person-years)a
Hazard ratio (95% CI)
Crude Adjustedb,c
SSRIs 3,543,559 258 19.2 1.00 [Reference] 1.00 [Reference]
Venlafaxine 436,155 36 22.2 1.15 (0.81–1.63) 1.17 (0.83–1.64)
Milnacipran 37,577 0 0.0
Duloxetine 247,250 12 12.6 0.70 (0.39–1.24) 0.54 (0.28–1.02)
Mianserin 293,484 29 21.5 1.43 (0.97–2.10) 0.90 (0.58–1.41)
Mirtazapine 128,593 15 32.8 1.65 (0.98–2.77) 1.17 (0.67–2.02)
Tianeptine 181,289 24 31.6 1.93 (1.27–2.94) 1.35 (0.82–2.23)
Agomelatine 98,918 8 24.6 1.18 (0.58–2.38) 1.07 (0.51–2.23)
Table 3  Odds ratios for hospitalization due to serious liver injury associated with antidepressant of interest versus selective serotonin reuptake 
inhibitors (SSRIs) in each case-time-control study performed by antidepressant of interest
CI confidence interval, SSRIs selective serotonin reuptake inhibitors
a Eligible profiles in each case-time-control study performed by antidepressant of interest: individuals with reimbursements for both (1) antide-
pressant of interest in the absence of SSRIs during one of the two periods (i.e., risk or reference) and (2) SSRIs in the absence of antidepressant 
of interest during the other period
b Number of cases with reimbursements for both (1) antidepressant of interest in the absence of SSRIs during the reference period and (2) SSRIs 
in the absence of antidepressant of interest during the risk period
c Number of cases with reimbursements for both (1) antidepressant of interest in the absence of SSRIs during the risk period and (2) SSRIs in the 
absence of antidepressant of interest during the reference period
d Adjusted for variations in drugs potentially associated with hepatotoxicity and other antidepressant reimbursement between reference and risk 
periods
Antidepressant of interest in each case-
time-control  studya
Cases Odds ratio (95% CI)
Reference period (n)b Risk period (n)c Crude Adjustedd
Venlafaxine 21 28 1.00 (0.56–1.81) 0.94 (0.51–1.72)
Milnacipran 5 2 0.43 (0.08–2.36) 0.86 (0.12–5.98)
Duloxetine 13 18 1.09 (0.52–2.30) 1.15 (0.53–2.53)
Mianserin 16 21 1.07 (0.54–2.11) 0.91 (0.42–1.97)
Mirtazapine 11 13 0.93 (0.40–2.18) 1.13 (0.43–3.00)
Tianeptine 17 7 0.94 (0.37–2.36) 1.06 (0.40–2.82)
Agomelatine 5 4 0.69 (0.18–2.69) 0.87 (0.12–6.34)
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was the case for previous observational studies conducted 
for duloxetine [9, 10].
To our knowledge, the present study is the first to com-
pare the risk of the hepatotoxicity of antidepressants both in 
real life and on the basis of such a large (5 million treatment 
initiators) representative nationwide sample. Its sample size 
warranted identifying rare outcomes such as serious, includ-
ing fatal, DILIs. The study also utilized the large amount of 
information provided by the SNIIRAM database to control 
for the main potential confounders by means of propensity 
scores, thereby providing more reliable estimates compared 
with classic multivariate models in the event of rare out-
comes [40]. It is also likely that using an active comparator 
minimized the influence of measured and unmeasured differ-
ences in patient characteristics linked with both antidepres-
sant use and the risk of hepatotoxicity [41]. Moreover, the 
conclusions remained unchanged in several sensitivity analy-
ses testing the effect of a broader event definition, longer 
follow-up (i.e., 12 months, even if liver-related events gener-
ally appear in the 6 months after drug initiation), liver moni-
toring or excluding patients with a single reimbursement of 
antidepressant. Finally, the case-time-control design used as 
a secondary approach to better control for potential unmeas-
ured invariant confounders confirmed the conclusions.
This study also has several limitations. The data were 
fully anonymized so accessing the original medical files to 
complement and ascertain clinical information on cases of 
liver injury was not possible. Therefore, the predictive posi-
tive value of the ICD-10 codes used to identify these cases 
without clinical validation could be debated [19] and the 
incidence rates obtained may not reflect true incidence rates 
of DILI. However, given the type of hepatotoxicity consid-
ered—serious cases leading to hospitalization or death—and 
the fact that making the definition broader did not alter the 
results, it is likely that this bias, if any, did not have a marked 
influence on the results. Moreover, it would apply the same 
way in each comparison group and would not have masked 
a significant excess risk of hepatotoxicity in users of the 
antidepressants of interest compared with SSRIs.
5  Conclusion
This study conducted on almost 5 million antidepressant 
initiators did not provide any evidence of an increased risk 
of serious liver injury associated with SNRIs (venlafax-
ine, milnacipran and duloxetine) or ‘other antidepressants’ 
(mianserin, mirtazapine, tianeptine and agomelatine) when 
compared with SSRIs in real-life settings. These findings 
could reflect an inherent lack of difference in risk between 
the drug classes, or the fact that individuals with higher sus-
ceptibility to drug-induced liver injury are not prescribed 
drugs considered to be more hepatotoxic.
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